Reports Q3 revenue $149.0M, consensus $142.52M. Cash and cash equivalents and marketable securities were $482.1M as of September 30, 2025.”Our team delivered a solid third quarter, and we continue to see notable enthusiasm for our single cell and spatial products,” said Serge Saxonov, CEO. “Our strong balance sheet and disciplined execution give us confidence to navigate the current environment, while our technology leadership and innovation position us to win and drive long-term growth.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings
- Cathie Wood Boosts Biotech and DraftKings Stakes, Trims Shopify
- Cathie Wood’s ARK Investment buys 222K shares of 10x Genomics today
- Cathie Wood Trims Exposure to AMD and Other U.S. Tech Favorites, Doubles Down on Baidu and Biotech Plays
- 10x Genomics announces partnership with Anthropic